Medical-device reimbursement listing

01Overview and value chain#

Markers EC: Medical-device coding, coverage & reimbursement listing services | OECD: Bioeconomy policy & governance | Regulator: FDA (US)

Medical-device reimbursement listing is a B2B services category in which specialist consultancies secure the CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings a medical device needs to be paid for in clinical use — a step distinct from, and often more commercially decisive than, FDA clearance itself. MCRA runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy. Avalere Health integrates clinical, coding and reimbursement strategy from early development, arguing that early-integrated strategies transform market-access challenges into successful launches with clear coverage and payment pathways. Boston Strategic Partners combines business and clinical strategy with health-economics and outcomes research (HEOR) and medical/technical writing to support device reimbursement dossiers. Emergo by UL, a global QA/RA consulting firm, extends its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance. Real Endpoints is a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices. Vintura, based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device or medicine can offer and what patients actually receive.

The key directions of medical-device reimbursement listing are:

1. CPT/HCPCS coding strategy: securing or navigating the billing codes (Current Procedural Terminology, Healthcare Common Procedure Coding System) a device needs for a provider to bill for its use.
2. Payer coverage-policy navigation: working with commercial insurers and public payers to establish a coverage policy under which the device is eligible for payment.
3. Health-economics and outcomes research (HEOR): building the clinical and economic evidence dossier payers require to justify a coverage or reimbursement decision.
4. European and national reimbursement-system policy shaping: advising on the specific health-technology-assessment and reimbursement-listing processes of individual national systems outside the US.

Sectoral value chain#

[FDA clearance/approval] ──> [CPT/HCPCS coding strategy] ──> [Payer coverage-policy submission]
                                                                    │
                                                        (HEOR evidence-dossier development)
                                                                    │
              [Ongoing coverage-policy monitoring] <──── [Reimbursement decision & listing] <─── [Payer review & negotiation]

Value chain levels#

Cross-cutting technologies of the sector:

• CPT/HCPCS coding strategy: the specific process of determining and securing the billing codes a medical device needs for a provider to be paid for its use.
• Payer coverage-policy analytics: structured tracking and analysis of commercial and public payer coverage policies relevant to a specific device category.
• Market-access consulting: integrated advisory services combining regulatory, coding, coverage and HEOR expertise to build a full reimbursement pathway.

02US#

The United States hosts the largest concentration of medical-device reimbursement consultancies, several combining FDA regulatory practices with dedicated coding and payer-coverage expertise.

MCRA’s combined regulatory-reimbursement practice, Avalere’s integrated coding strategy, Boston Strategic Partners’ HEOR support, Emergo by UL’s global QA/RA-adjacent work, Real Endpoints’ payer-coverage focus#

• MCRA: runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy.
• Avalere Health: integrates clinical, coding and reimbursement strategy from early development, transforming market-access challenges into launches with clear coverage and payment pathways.
• Boston Strategic Partners: combines business and clinical strategy with health-economics and outcomes research and medical/technical writing to support device reimbursement dossiers.
• Emergo by UL: a global QA/RA consulting firm extending its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance.
• Real Endpoints: a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices.

03CN#

China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese medical-device reimbursement consultancies searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Medical-device reimbursement listing in China runs through the National Healthcare Security Administration’s centralized procurement and medical-insurance catalog processes rather than the payer-by-payer model common in the US and Europe, and specialist consulting practices supporting this process could not be confirmed in this screen.

China’s centralized medical-insurance listing process without a confirmed specialist consultancy#

• Centralized listing model: device reimbursement in China runs through the National Healthcare Security Administration’s centralized procurement and medical-insurance catalog listing process, structurally distinct from the multi-payer US model.
• Domestic gap: no Chinese-headquartered medical-device reimbursement consultancy confirmed by a live 2026 source was found during this screen.

04EU#

Europe hosts market-access and policy-shaping consultancies working across the fragmented national health-technology-assessment and reimbursement-listing systems of individual EU member states.

Vintura’s policy-shaping and commercial-strategy practice across European reimbursement systems#

• Vintura: based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device can offer and what patients actually receive under national coverage decisions.

05Leading companies and research institutes#

06Tech stack and innovations#

The medical-device reimbursement listing stack combines regulatory-adjacent coding expertise with structured payer-coverage analytics and health-economics evidence development:

1. CPT/HCPCS coding strategy:
   • Firms such as MCRA and Avalere Health determine and secure the specific billing codes a device needs, a step that directly determines whether providers can be paid for using it.
2. Payer coverage-policy analytics:
   • Real Endpoints specializes in tracking and navigating commercial and private-payer coverage policy and prior-authorization requirements specific to a device category.
3. HEOR evidence development:
   • Boston Strategic Partners builds the health-economics and outcomes research evidence dossier payers require to justify a coverage or reimbursement decision.

07Value chains and production pipelines#

Industrial pipeline for a medical-device reimbursement listing engagement#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Regulatory clearance     │ ───> │ 2. CPT/HCPCS coding         │
│                                  │      │    strategy                       │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Payer review &           │ <─── │ 3. Coverage-policy          │
│    negotiation                  │      │    submission                     │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Reimbursement decision   │ ───> │ 6. Ongoing coverage-        │
│    & listing                    │      │    policy monitoring              │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Regulatory clearance

The device receives FDA clearance or approval, the prerequisite step before a reimbursement pathway can be pursued.

Stage 2: CPT/HCPCS coding strategy

The consultancy determines and secures the billing codes a provider needs to bill for the device’s use, requesting a new code where none exists.

Stage 3: Coverage-policy submission

Evidence supporting the device’s clinical and economic value is submitted to commercial and public payers to establish a formal coverage policy.

Stage 4: Payer review and negotiation

Payers review the submission, often requesting additional health-economics evidence or negotiating specific coverage terms before deciding.

Stage 5: Reimbursement decision and listing

The payer issues a coverage decision, and where applicable, the device is added to a formal reimbursement listing that providers can bill against.

Stage 6: Ongoing coverage-policy monitoring

The consultancy tracks payer coverage-policy changes and prior-authorization requirements that could affect the device’s ongoing reimbursement status.